NCT02442206

Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients

A Randomized, Double-blinded, Single-center, Placebo Controlled, Cross-over Study to Assess the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) on Cardiac Function in Patients With Chronic Obstructive Pulmonary Disease (COPD)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 62 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

This mechanistic study is a single-center, randomized, double-blind, placebo-controlled, cross-over study to evaluate the effect of dual bronchodilation with QVA149 on cardiac and lung function parameters in hyperinflated COPD patients.

Conditions

• Chronic Obstructive Pulmonary Disease, COPD

Interventions

Type	Name	Description
DRUG	QVA149	QVA149 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily
DRUG	Placebo	Placebo to QVA140 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily

Timeline

• Start date: 2015-05-18
• Primary completion: 2017-04-20
• Completion: 2017-05-15
• First posted: 2015-05-13
• Last updated: 2019-01-03
• Results posted: 2018-12-03

Locations

1 site across 1 country: Germany